E. Ramsay Camp

Dr. E. Ramsay Camp

Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of the American College of Surgeons
Verified
Journal Article
Open access
E. Ramsay CampE. Ramsay Camp
E. Ramsay Camp
BGBrielle Gerry
Brielle Gerry
DCDongjun Chung
Dongjun Chung
VFVictoria Findlay
Victoria Findlay
MFMarvella Elizabeth Ford
Marvella Elizabeth Ford
TCThomas Curran
Thomas Curran

1 February 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
ZGZachary Gao
Zachary Gao
JAJoseph Azar
Joseph Azar
HZHuili Zhu
Huili Zhu
SWSophia Williams-Perez
Sophia Williams-Perez
SKSung Wook Kang
Sung Wook Kang
E. Ramsay CampE. Ramsay Camp
E. Ramsay Camp
Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvironment (TiME). However, the PDAC TiME is heterogeneous and harbors favorable tumor-infiltrating lymphocyte (TIL) populations. Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop within non-lymphoid tissue under chronic inflammation in multiple contexts, including cancers. Our current understanding of their role within the PDAC TiME remains limited; TLS are complex structures with multiple anatomic features such as location, density, and maturity that may impact clinical outcomes such as survival and therapy response in PDAC. Similarly, our understanding of methods to manipulate TLS is an actively developing field of research. TLS may function as anti-tumoral immune niches that can be leveraged as a therapeutic strategy to potentiate both existing chemotherapeutic regimens and potentiate future immune-based therapeutic strategies to improve patient outcomes. This review seeks to cover anatomy, relevant features, immune effects, translational significance, and future directions of understanding TLS within the context of PDAC.

28 February 2022 in The American Journal of Surgery
Verified
Journal Article
Closed access
TMT. Alston Mickel
T. Alston Mickel
OKOnur Cagri Kutlu
Onur Cagri Kutlu
ESEric J. Silberfein
Eric J. Silberfein
CHCary Hsu
Cary Hsu
CCChristy Y. Chai
Christy Y. Chai
E. Ramsay CampE. Ramsay Camp
E. Ramsay Camp

1 July 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
WCWilson L. da Costa
Wilson L. da Costa
E. Ramsay CampE. Ramsay Camp
E. Ramsay Camp
ATAaron P. Thrift
Aaron P. Thrift
PURPOSE: Evidence on health disparities among patients treated with multimodality therapy protocols is still limited. We aimed to evaluate the associations between patient-level and system-level factors and the receipt of guideline-concordant therapy among patients with esophageal adenocarcinoma (EA). METHODS: This is a national cohort study of patients with stage I-III EA in the National Cancer Database (2006-2018) treated with either upfront resection or neoadjuvant therapy followed by surgery. Clinical and pathologic staging data were used for defining guideline-concordant therapy. Logistic regression models were built to identify independent associations between deviations from treatment guidelines and clinical, sociodemographic, and hospital-related factors. RESULTS: Among 18,803 patients with EA treated at 1,049 hospitals, 4,511 had an endoscopic resection, 4,866 had upfront resection, and 9,426 had neoadjuvant therapy followed by surgery. A total of 16,002 patients (85.1%) received guideline-concordant therapy. Patients who were age 70 years or older (odds ratio [OR] 1.35; 95% CI, 1.14 to 1.60), had a Charlson-Deyo modified score of ≥ 1, and were treated at hospitals with a safety-net burden of ≥ 10% (OR 1.13; 95% CI, 1.02 to 1.25) had higher risk of deviations from guidelines, whereas treatment at high-volume facilities (OR 0.84; 95% CI, 0.74 to 0.95) and diagnosis after 2011 decreased this risk. Relative to cT0-1N0 patients, those with cT2N0 disease had the highest risk of deviations from guideline-concordant therapy (OR 3.76; 95% CI, 3.30 to 4.29). Among patients treated at high-volume facilities, safety-net burden over 10% increased the risk of deviations (OR 1.26; 95% CI, 1.01 to 1.57). CONCLUSION: The delivery of guideline-concordant therapy among patients with EA varies significantly across clinical stage groups and is associated with several sociodemographic disparities. This knowledge should be a resource for future quality improvement strategies intended to address inequitable care within vulnerable populations.

10 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
HJHee-Jin Jang
Hee-Jin Jang
MPMeera Patel
Meera Patel
DWDaniel Y. Wang
Daniel Y. Wang
SKSung Wook Kang
Sung Wook Kang
JCJong Min Choi
Jong Min Choi
BBBryan M. Burt
Bryan M. Burt
Purpose: Immune checkpoint inhibitors (ICI) have limited efficacy in pleural mesothelioma. We investigated the role of Dickkopf WNT signaling pathway inhibitor 3 (DKK3) in overcoming treatment resistance. Patients and Methods: We performed preclinical studies to elucidate DKK3’s role in ICI-resistant mouse mesothelioma. Based on these findings, we conducted a single-arm, phase II clinical trial of a combination of Ad-SGE-DKK3 and nivolumab for chemotherapy-refractory epithelioid pleural mesothelioma, with the objective response rate as the primary outcome. Results: DKK3 was significantly reduced in human epithelioid mesothelioma. Overexpression of DKK3 in cancer cells activated the p53 pathway, enhanced glycolysis, increased surface PD-L1, and reduced extracellular vesicle secretion and the colony-stimulating factor 1. DKK3 sensitized the tumor immune microenvironment to ICIs and enabled the eradication of tumors by PD-1 blockade. In our trial, 12 patients received intratumoral Ad-SGE-DKK3 plus intravenous nivolumab. The objective response rate was 16.6%, and 41.7% had stable disease, for a 58.3% rate of durable clinical response. The median overall survival was 14.5 months, and the median progression-free survival was 4.5 months. Grade 3 adverse events occurred in 41.7% of patients. Serial tumor biopsies and serum analyses revealed that patients with durable clinical response had increased tumor-infiltrating bulk and effector memory CD8 T cells, reduced circulating memory CD8 T cells, and sustained lower soluble mesothelin and the colony-stimulating factor 1 levels compared with progressors. Conclusions: Combination Ad-SGE-DKK3 plus nivolumab demonstrated a tolerable safety profile and potential efficacy in patients with chemotherapy-refractory epithelioid pleural mesothelioma.

1 October 2024 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
HJHarinarayanan Janakiraman
Harinarayanan Janakiraman
ZGZachary Gao
Zachary Gao
YZYun Zhu
Yun Zhu
JDJiangling Dong
Jiangling Dong
SBScott A. Becker
Scott A. Becker
E. Ramsay CampE. Ramsay Camp
E. Ramsay Camp
Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition